Unlike GLP-1s, PCSK9 inhibitors are a near "free lunch." Discovered from a genetic mutation in a population with virtually no heart disease, these drugs dramatically lower bad cholesterol with minimal trade-offs, making them an ideal preventative tool.

The upcoming PDUFA date for Arvinus's Vepdegestrant is more than a milestone for breast cancer treatment. Its approval would be the first for a PROTAC, validating the rationally designed targeted protein degrader platform and boosting confidence across a wide range of diseases beyond oncology.

CEO Dan Schmitt outlines a three-part test for a new drug: it must effectively engage its intended biological target, avoid interacting with other enzymes to prevent toxicity, and be deliverable to a patient in sufficient quantities to be effective. This framework simplifies the core challenges of drug development.

While biologics get much attention, a significant investment opportunity lies in next-generation small molecules like degraders and hetero-bifunctional molecules. These advanced chemistries allow companies to target known, de-risked biological pathways in novel ways, hitting previously 'undruggable' targets and creating powerful new drugs.

Instead of targeting rare, single-gene mutations, Medera's therapy restores a protein universally downregulated in most forms of heart failure. This "umbrella pathway" strategy allows a single drug to treat multiple cardiac diseases, whether genetic or acquired, dramatically expanding the potential patient population from rare to common diseases.

Drugs like PCSK9 inhibitors struggle with adoption because they treat asymptomatic conditions like high cholesterol. Without the immediate, tangible feedback seen with GLP-1s, it's harder for patients to stay compliant with treatment for a silent, long-term risk.

The new menin inhibitor, enzomenib, demonstrates potentially superior response rates (CR/CRH of 40-60%) compared to existing agents (~23%). Crucially, early data shows no QTc prolongation, a significant dose-limiting toxicity for current menin inhibitors, suggesting a major safety improvement for this drug class.

Recent Phase 3 data show oral small molecules succeeding in complex indications. Roche's phenobrutinib met its endpoint in progressive multiple sclerosis, and Bridge Biopharma's Imfegratinib improved height velocity in achondroplasia. This signals a potential shift toward more convenient, patient-friendly oral therapies in areas historically reliant on injectables.

Beyond accelerating timelines, AI's real value lies in its ability to design molecules for targets previously considered 'hard-to-drug.' These models operate on different principles than traditional lab methods and are indifferent to historical challenges, opening up entirely new therapeutic possibilities.